INSM vs MRNA
Insmed Incorporated and Moderna, both Healthcare
Moderna is the larger company at $25B against $23B. Over the past year MRNA returned +93% against -30% for INSM. The RyuScore puts MRNA ahead, 48 against 18 out of 100.
| Figure | INSM | MRNA |
|---|---|---|
| Last close | $101 | $62.96 |
| Market cap | $23B | $25B |
| 1-year return | -30% | +93% |
| 5-year return | +269% | -81% |
| RyuScoresector-relative, 1–10 | 18/100 | 48/100 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
Insmed Incorporated
Revenue of $425M in Q2 2026, net income null. Its largest reported line is United States, 60% of the disclosed total.
Moderna
Revenue of $145M in Q2 2026, net income null. Its largest reported line is COVID19, 63% of the disclosed total.
Open these two in the interactive comparison to add more names, change the period or see the correlation.